NASDAQ:INCY

Incyte Stock Forecast, Price & News

$90.66

-1.38 (-1.50 %)

(As of 01/15/2021 03:29 PM ET)

Add

Compare

Today's Range

$89.33

Now: $90.66▼

$92.51

50-Day Range

$80.96

MA: $86.44▼

$94.31

52-Week Range

$62.48

Now: $90.66▼

$110.36

Volume21,391 shs

Average Volume1.27 million shs

Market Capitalization$19.85 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.96

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naÃ¯ve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

MarketRank^™

Overall MarketRank^™

1.86 out of 5 stars

Medical Sector

80th out of 1,480 stocks

Commercial Physical Research Industry

3rd out of 33 stocks

3.3 Analyst's Opinion

Consensus Rating
Incyte has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 12 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $103.56, Incyte has a forecasted upside of 15.4% from its current price of $89.71.
Amount of Analyst Coverage
Incyte has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.1 Community Rank

Outperform Votes
Incyte has received 1,148 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Incyte has received 727 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Incyte has received 61.23% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote “Outperform” if you believe INCY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Incyte does not currently pay a dividend.
Dividend Growth
Incyte does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Incyte insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 16.10% of the stock of Incyte is held by insiders.
Percentage Held by Institutions
91.37% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Incyte are expected to grow in the coming year, from ($1.42) to $2.68 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Incyte is -57.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Incyte is -57.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Incyte has a PEG Ratio of 1.00. PEG Ratios around 1 indicate that a company is correctly valued.
Price to Book Value per Share Ratio
Incyte has a P/B Ratio of 7.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:INCY

Previous Symbol

CUSIP45337C10

CIK879169

Webwww.incyte.com

Phone302-498-6700

Employees1,456

Debt

Debt-to-Equity Ratio0.01

Current Ratio3.56

Quick Ratio3.53

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E Growth1

Sales & Book Value

Annual Sales$2.16 billion

Price / Sales9.20

Cash Flow$2.42 per share

Price / Cash Flow37.50

Book Value$12.06 per share

Price / Book7.52

Profitability

EPS (Most Recent Fiscal Year)$2.23

Net Income$446.91 million

Net Margins-13.62%

Return on Equity-13.66%

Return on Assets-9.98%

Miscellaneous

Outstanding Shares218,996,000

Market Cap$19.85 billion

Next Earnings Date2/11/2021 (Estimated)

OptionableOptionable

$90.66

-1.38 (-1.50 %)

(As of 01/15/2021 03:29 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

Incyte (NASDAQ:INCY) Frequently Asked Questions

How has Incyte's stock price been impacted by COVID-19?

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, INCY stock has increased by 24.7% and is now trading at $89.64.
View which stocks have been most impacted by COVID-19.

Is Incyte a buy right now?

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 9 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Incyte stock.
View analyst ratings for Incyte or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Incyte?

Wall Street analysts have given Incyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Incyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Incyte.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its quarterly earnings data on Thursday, November, 5th. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.46 by $0.23. The biopharmaceutical company earned $620.64 million during the quarter, compared to the consensus estimate of $622.48 million. Incyte had a negative net margin of 13.62% and a negative return on equity of 13.66%. The firm's revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.82 EPS.
View Incyte's earnings history.

What price target have analysts set for INCY?

21 analysts have issued 1-year target prices for Incyte's shares. Their forecasts range from $86.00 to $124.00. On average, they expect Incyte's share price to reach $103.56 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price.
View analysts' price targets for Incyte or view Wall Street analyst' top-rated stocks.

Who are some of Incyte's key competitors?

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Novavax (NVAX) and United Therapeutics (UTHR).
View all of INCY's competitors.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Who are Incyte's key executives?

Incyte's management team includes the following people:

Ms. Christiana Stamoulis, Exec. VP & CFO (Age 50, Pay $1.2M)
Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 58, Pay $847.81k)
Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA, Exec. VP & GM of North America (Age 63, Pay $803.14k)
Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 54, Pay $937.73k)
Mr. Michael James Morrissey, Exec. VP & Head of Global Technical Operations (Age 57)
Dr. Dashyant Dhanak Ph.D., Exec. VP & Chief Scientific Officer (Age 60)
Mr. Michael Booth DPhil, Divisional VP of Investor Relations & Corp. Social Responsibility (Age 50)
Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel (Age 55)
Ms. Pamela M. Murphy, VP of Investor Relations & Corp. Communications (Age 70)

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.01%), Louisiana State Employees Retirement System (0.01%), Crossmark Global Holdings Inc. (0.01%), IFM Investors Pty Ltd (0.01%) and NuWave Investment Management LLC (0.00%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.

Which major investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., State of Alaska Department of Revenue, and NuWave Investment Management LLC. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte or view top insider-selling stocks.

Which major investors are buying Incyte stock?

INCY stock was bought by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, and IFM Investors Pty Ltd.
View insider buying and selling activity for Incyte or or view top insider-buying stocks.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $89.64.

How big of a company is Incyte?

Incyte has a market capitalization of $19.63 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here